Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Obstetrics and Gynecology
Volume 2017, Article ID 4801650, 4 pages
https://doi.org/10.1155/2017/4801650
Case Report

Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare

Department of Obstetrics and Gynecology, Nagasaki Harbor Medical Center City Hospital, 6-39 Shinchimachi, Nagasaki-shi, Nagasaki 850-8555, Japan

Correspondence should be addressed to Terumi Tanigawa; moc.liamg@awaginatygbo

Received 19 January 2017; Accepted 5 March 2017; Published 6 April 2017

Academic Editor: Yoshio Yoshida

Copyright © 2017 Terumi Tanigawa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W.-L. Wang, R. Soslow, M. Hensley et al., “Histopathologic prognostic factors in stage I leiomyosarcoma of the uterus: a detailed analysis of 27 cases,” American Journal of Surgical Pathology, vol. 35, no. 4, pp. 522–529, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. D. S. Kapp, J. Y. Shin, and J. K. Chan, “Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy,” Cancer, vol. 112, no. 4, pp. 820–830, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Gadducci, F. Landoni, E. Sartori et al., “Uterine leiomyosarcoma: analysis of treatment failures and survival,” Gynecologic Oncology, vol. 62, no. 1, pp. 25–32, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Naaman, D. Shveiky, I. Ben-Shachar, A. Shushan, J. Mejia-Gomez, and A. Benshushan, “Uterine sarcoma: prognostic factors and treatment evaluation,” Israel Medical Association Journal, vol. 13, no. 2, pp. 76–79, 2011. View at Google Scholar · View at Scopus
  5. A. I. Spira and D. S. Ettinger, “The use of chemotherapy in soft-tissue sarcomas,” Oncologist, vol. 7, no. 4, pp. 348–359, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Sutton, J. A. Blessing, and J. H. Malfetano, “Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 62, no. 2, pp. 226–229, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Leyvraz, M. Zweifel, G. Jundt et al., “Swiss Group for Clinical Cancer Research. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas,” Annals of Oncology, vol. 17, no. 4, pp. 646–651, 2006. View at Publisher · View at Google Scholar
  8. S. Sleijfer, I. Ray-Coquard, Z. Papai et al., “Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC Study 62043),” Journal of Clinical Oncology, vol. 27, no. 19, pp. 3126–3132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. F. A. B. Schutz, T. K. Choueiri, and C. N. Sternberg, “Pazopanib: clinical development of a potent anti-angiogenic drug,” Critical Reviews in Oncology/Hematology, vol. 77, no. 3, pp. 163–171, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. W. T. A. Van Der Graaf, J.-Y. Blay, S. P. Chawla et al., “Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial,” The Lancet, vol. 379, no. 9829, pp. 1879–1886, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. K.-J. Yun, W. Kim, E. H. Kim et al., “Accelerated disease progression after discontinuation of sorafenib in a patient with metastatic papillary thyroid cancer,” Endocrinology and Metabolism, vol. 29, no. 3, pp. 388–393, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. J. E. Chaft, G. R. Oxnard, C. S. Sima, M. G. Kris, V. A. Miller, and G. J. Riely, “Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design,” Clinical Cancer Research, vol. 17, no. 19, pp. 6298–6303, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Wolter, B. Beuselinck, S. Pans, and P. Schffski, “Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors,” Acta Oncologica, vol. 48, no. 4, pp. 621–624, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. I. M. E. Desar, S. F. Mulder, A. B. Stillebroer et al., “The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases,” Acta Oncologica, vol. 48, no. 6, pp. 927–931, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Iacovelli, F. Massari, L. Albiges et al., “Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma,” European Urology, vol. 68, no. 1, pp. 154–160, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. D. D. Von Hoff, “There are no bad anticancer agents, only bad clinical trial designs- twenty-first Richard and Hinda Rosenthal foundation award lecture,” Clinical Cancer Research, vol. 4, no. 5, pp. 1079–1086, 1998. View at Google Scholar · View at Scopus
  17. G. D. Demetri, S. P. Chawla, M. Von Mehren et al., “Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules,” Journal of Clinical Oncology, vol. 27, no. 25, pp. 4188–4196, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. G. R. Oxnard, M. E. Arcila, J. Chmielecki, M. Ladanyi, V. A. Miller, and W. Pao, “New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosinekinase inhibitors in lung cancer,” Clinical Cancer Research, vol. 17, no. 17, pp. 5530–5537, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Bennouna, J. Sastre, D. Arnold et al., “Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial,” The Lancet Oncology, vol. 14, no. 1, pp. 29–37, 2013. View at Publisher · View at Google Scholar · View at Scopus